Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -41,066 | -38,776 | -30,527 | -23,465 | -13,294 |
| Depreciation Amortization | 33 | 32 | 41 | 36 | 35 |
| Other Working Capital | 4,678 | 4,968 | 3,957 | 942 | 641 |
| Other Operating Activity | 3,390 | 2,720 | 2,221 | 1,886 | 1,770 |
| Operating Cash Flow | $-32,965 | $-31,056 | $-24,308 | $-20,601 | $-10,848 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 30,000 | 10,000 | 30,000 | N/A | N/A |
| Common Stock Issued | 10,033 | N/A | 6,814 | 263 | 50,469 |
| Dividend Paid | N/A | N/A | N/A | N/A | -394 |
| Financing Cash Flow | $40,033 | $10,000 | $36,814 | $263 | $50,075 |
| Beginning Cash Position | 18,592 | 39,648 | 27,142 | 47,480 | 8,253 |
| End Cash Position | 25,660 | 18,592 | 39,648 | 27,142 | 47,480 |
| Net Cash Flow | $7,068 | $-21,056 | $12,506 | $-20,338 | $39,227 |
| Free Cash Flow | |||||
| Operating Cash Flow | -32,965 | -31,056 | -24,308 | -20,601 | -10,848 |
| Free Cash Flow | -32,965 | -31,056 | -24,308 | -20,601 | -10,848 |